Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catabasis Pharma (CATB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,728
  • Shares Outstanding, K 71,040
  • Annual Sales, $ 500 K
  • Annual Income, $ -27,360 K
  • 36-Month Beta 0.56
  • Price/Sales 98.25
  • Price/Cash Flow N/A
  • Price/Book 1.07
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.73
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/08/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.22
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +48.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.63 +11.11%
on 10/18/18
0.88 -20.45%
on 10/03/18
-0.11 (-13.58%)
since 09/19/18
3-Month
0.61 +14.75%
on 08/20/18
0.88 -20.45%
on 10/03/18
-0.05 (-6.67%)
since 07/19/18
52-Week
0.61 +14.75%
on 08/20/18
2.38 -70.59%
on 02/13/18
-1.67 (-70.46%)
since 10/19/17

Most Recent Stories

More News
Bet on Rising P/E Investing With These 5 Top-Ranked Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

CATB : 0.70 (+1.45%)
PCH : 36.53 (+1.28%)
EBAY : 28.75 (-8.87%)
NLST : 0.3800 (-5.47%)
TLRD : 21.94 (-2.05%)
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the initiation of PolarisDMD, the Company's Phase 3 trial for edasalonexent...

CATB : 0.70 (+1.45%)
Catabasis Pharmaceuticals to Present New Edasalonexent Clinical Results and Phase 3 Trial Design in Duchenne Muscular Dystrophy at the World Muscle Society Congress

-- Presentations on MoveDMD Clinical Results and Polaris DMD Phase 3 Design -

CATB : 0.70 (+1.45%)
Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study

Spectrum Pharma (SPPI) amends poziotinib study protocol to include two cohorts to evaluate it in first-line lung cancer.

SPPI : 13.18 (-1.57%)
CATB : 0.70 (+1.45%)
AZN : 39.21 (+0.67%)
PCRX : 47.00 (-2.51%)
Catabasis Pharmaceuticals Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Catabasis Pharmaceuticals Inc (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern...

CATB : 0.70 (+1.45%)
Catabasis Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate...

CATB : 0.70 (+1.45%)
Catabasis Pharmaceuticals to Report Second Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, August 9

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report second quarter 2018 financial results before the NASDAQ Global Market open on...

CATB : 0.70 (+1.45%)
Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat

Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.

LGND : 187.52 (-4.84%)
CATB : 0.70 (+1.45%)
KERX : 3.21 (-0.31%)
ENTA : 78.97 (+0.16%)
Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss

Intrexon (XON) incurs narrower-than-expected loss but revenues missed mark in the first quarter of 2018.

LGND : 187.52 (-4.84%)
CATB : 0.70 (+1.45%)
ENTA : 78.97 (+0.16%)
XON : 13.95 (-3.59%)
Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up

Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.

LGND : 187.52 (-4.84%)
CATB : 0.70 (+1.45%)
ENTA : 78.97 (+0.16%)
ECYT : 23.48 (+0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CATB with:

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Key Turning Points

2nd Resistance Point 0.74
1st Resistance Point 0.72
Last Price 0.70
1st Support Level 0.68
2nd Support Level 0.67

See More

52-Week High 2.38
Fibonacci 61.8% 1.70
Fibonacci 50% 1.50
Fibonacci 38.2% 1.29
Last Price 0.70
52-Week Low 0.61

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar